Crystal Lake, Illinois, May 1, 2025 — AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year.
First Quarter 2025 Highlights (compared to the prior year quarter)
• Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease
• Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 million
• Adjusted EBITDA margin of 20.7%, with margin expansion of 120 basis points
• Reported earnings per share of $1.17
• Adjusted earnings per share of $1.20, excluding the impact of currency effects and change in tax rate, earnings per share would have increased 5%
• Pharma’s proprietary drug delivery systems* reported sales grew 2% and core sales grew 4% in the quarter
• Returned approximately $110 million to shareholders, including $80 million of share repurchases
“Our pharma and closures segments delivered solid results with increased product sales in the quarter. We saw growing demand for our dosing, dispensing and protection technologies across a number of end markets including central nervous system therapeutics, emergency medicines, weight and diabetes management, as well as food, beverage and personal care. We also returned about $110 million to shareholders through dividends and share repurchases, more than half a million shares were repurchased for $80 million,” said Stephan B. Tanda, Aptar President and CEO.
